1,2,3-triazoles (including Hydrogenated) Patents (Class 548/255)
-
Publication number: 20140065070Abstract: The present application relates to methods of preparing radiohalogenated compounds, to compounds useful in such methods and to radiohalogenated compounds useful for imaging and/or therapy.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: MCMASTER UNIVERSITYInventors: John Valliant, Alla Darwish, Stephanie Rathmann, Afaf Genady
-
Publication number: 20140066632Abstract: A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion in human blood plasma to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt, Cu(II) ion in the presence of a reducing agent, or copper metal.Type: ApplicationFiled: November 12, 2013Publication date: March 6, 2014Applicant: The Scripps Research InstituteInventors: K. Barry SHARPLESS, Valery FOKIN, Vsevold A. ROSTOVTSEV, Luke GREEN, Fahmi HIMO
-
Publication number: 20140066631Abstract: Provided is a method of separating carbon nanotubes, the method comprising: forming first carbon nanotubes having a first functional group, forming a substrate having a second functional group, and causing the first carbon nanotubes to adhere to the substrate by a click chemistry reaction between the first functional group and the second functional group.Type: ApplicationFiled: August 22, 2013Publication date: March 6, 2014Applicants: Gachon University of Industry-Academic Cooperation Foundation, Samsung Electronics Co., Ltd.Inventors: Tae-Yong KWON, Woo-Jae KIM, Hyung-Sam KIM
-
Publication number: 20140058058Abstract: The invention generally relates to functional polymers and hydrogels. More particularly, the invention provides versatile monomers and polymers with well-defined functionalities, e.g., polycarbonates and poly(ester-carbonates), compositions thereof, and methods for making and using the same. The invention also provides cytocompatible poly(ethylene glycol)-co-polycarobonate hydrogels (e.g., crosslinked by copper-free, strain-promoted “click” chemistry).Type: ApplicationFiled: February 24, 2012Publication date: February 27, 2014Applicant: University of Massachusetts Medical SchoolInventors: Jie Song, Jianwen Xu
-
Publication number: 20140051660Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, Q, and G are defined herein.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Applicant: Janssen Pharmaceutica NVInventors: Michael WINTERS, Zhihua Sui, Christopher Flores
-
Publication number: 20140051712Abstract: The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.Type: ApplicationFiled: December 16, 2011Publication date: February 20, 2014Inventors: John R. Cashman, Jarosiaw Kalisiak
-
Patent number: 8653070Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: December 14, 2010Date of Patent: February 18, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Hui Cao, Lu Ying, Yat Sun Or
-
Publication number: 20140045906Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: August 7, 2013Publication date: February 13, 2014Inventors: Melissa Fleury, Adam D. Hughes
-
Publication number: 20140046053Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: October 10, 2013Publication date: February 13, 2014Applicant: THERAVANCE, INC.Inventors: Roland Gendron, Melissa Fleury, Adam D. Hughes
-
Publication number: 20140038975Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.Type: ApplicationFiled: March 27, 2012Publication date: February 6, 2014Inventors: Matthew Frank Brown, Jinshan Michael Chen, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
-
Patent number: 8637555Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.Type: GrantFiled: October 29, 2004Date of Patent: January 28, 2014Assignees: Arena Pharmaceuticals, Inc., Merck & Co., Inc.Inventors: Graeme Semple, Thomas Schrader, Philip J. Skinner, Steven L. Colletti, Tawfik Gharbaoui, Jason E. Imbriglio, Jae-Kyu Jung, Rui Liang, Subharekha Raghavan, Darby Schmidt, James R. Tata
-
Publication number: 20140024815Abstract: A dendritic structure includes a core and repeating units, wherein the repeating units comprise units of the type ABxCy, wherein x is 2, 3, or 4, wherein y is 1, 2, or 3, wherein C is selected from the group consisting of azides and alkynes, and wherein every repeating unit is bound to at least one other unit with at least one bond selected from the group consisting of the group consisting of an ester, an amide, a thioether, an ether, a urethane, an amine, and an imine. Advantages include that a “one-pot” growth of the dendritic structure is possible. It is possible to have more functional groups in a dendritic structure. It is possible to add different functional groups simultaneously both to an inner layer and to an outer layer in a dendritic structure.Type: ApplicationFiled: September 25, 2013Publication date: January 23, 2014Applicant: POLYMER FACTORY SWEDEN ABInventors: Anders HULT, Michael MALKOCH, Per ANTONI
-
Publication number: 20140024680Abstract: The invention relates to novel arylpyrroline compounds of formula (I) which have excellent insecticidal activity and which can thus be used as an insecticide.Type: ApplicationFiled: January 9, 2013Publication date: January 23, 2014Applicant: Bayer Intellectual Property GmbHInventor: Bayer Intellectual Property GmbH
-
Publication number: 20140024837Abstract: A compound of Formula I or Formula II:Type: ApplicationFiled: August 30, 2013Publication date: January 23, 2014Applicant: UNIVERSITE DE MONTREALInventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
-
Publication number: 20140018541Abstract: Unsymmetrical bisazides containing chelating and non-chelating azido groups undergo chemoselective three-component copper(I)-catalyzed azide-alkyne conjugation reactions with two different alkyne molecules. In conjunction with the reactivity gap between aromatic and aliphatic alkynes, a bistriazole molecule can be generated with an excellent regioselectivity by mixing two alkynes and a bisazide in a single reaction container. This method is applicable in aqueous solutions at neutral pH, which may lend utilities in bioconjugation applications.Type: ApplicationFiled: July 15, 2013Publication date: January 16, 2014Applicant: The Florida State University Research Foundation, Inc.Inventors: Lei Zhu, Zhao Yuan, Gui-Chao Kuang
-
Publication number: 20140018318Abstract: The present invention provides inhibitors of a wide variety of serine hydrolase enzymes. The inhibitors of the present invention are N1- and N2-carbamoyl-1,2,3-triazole compounds such as those of Formula (I): in which N1, N2, and N3 are the nitrogen atoms at positions 1, 2, and 3, respectively, of the triazole ring, and R4, R5, R6 and R7 in Formula (I) are as described herein. Methods of inhibiting serine hydrolase enzymes and methods of preparing carbamoyl-1,2,3-triazole compounds also are described.Type: ApplicationFiled: April 5, 2012Publication date: January 16, 2014Applicant: The Scipps Research InstituteInventors: Benjamin Cravatt, Alexander Adibekian, Katsunori Tsuboi, Ku-Lung Hsu
-
Publication number: 20140011847Abstract: This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.Type: ApplicationFiled: August 15, 2013Publication date: January 9, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BUCK INSTITUTE FOR RESEARCH ON AGINGInventors: Lisa M. ELLERBY, Jonathan A. ELLMAN, Melissa J. LEYVA
-
Publication number: 20140011961Abstract: The present invention relates to a solid precursor in the form of an organic salt, the solid precursor having a solid support, a method for manufacturing same, and an application thereof. The solid precursor of the present invention enables omission of the [18F]fluoride refining process using additional cartridge, and the use of excessive phase-transfer catalyst, and can easily remove remaining substance after reaction through the solid support inside the precursor. The solid precursor of the present invention is very appropriate for an automated synthesis device as an all-in-one system that can carry out overall process of [18F]fluorosis reaction, when used by charging in a cartridge.Type: ApplicationFiled: December 13, 2011Publication date: January 9, 2014Inventors: Dae-Yoon Chi, Byoung-Se Lee, Jae-Hak Lee, So-Young Chu, Woon-Jung Jung, Hye-Rim Kwon
-
Publication number: 20140011997Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: September 12, 2013Publication date: January 9, 2014Applicant: THERAVANCE, INC.Inventors: Cameron Smith, Melissa Fleury, Roland Gendron, Ryan Hudson, Adam D. Hughes
-
Publication number: 20140005245Abstract: The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein A1, A2, A3, A4, R1, R2, G1, Q1 and Q2 are as defined in claim 1; or salts or N— oxides thereof.Type: ApplicationFiled: February 7, 2012Publication date: January 2, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Pierre Joseph Marcel Jung, Ottmar Franz Hueter, Peter Renold, Thomas Pitterna
-
Patent number: 8618144Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: GrantFiled: April 28, 2010Date of Patent: December 31, 2013Assignee: Merck Sharp & Dohme CorpInventors: Peter Lin, Lehua Chang, Scott D. Edmondson
-
Patent number: 8614233Abstract: A compound of Formula, (I) or Formula: (II).Type: GrantFiled: May 29, 2008Date of Patent: December 24, 2013Assignee: Universite de MontrealInventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
-
Patent number: 8609858Abstract: The present invention relates to novel spiro derivatives of parthenin prepared by the dipolar cycloaddition of various dipoles viz, benzonitrile oxides, nitrones, azides, nitrile ylide diazoalkane, nitrile imide, ozone, azomethine imides, azomethine ylides etc. with exocyclic double bond of C ring (?-methylene-?-butyrolactone). Representative compounds have been screened for their anticancer activity against different cancer cell lines. ICs0 value of these analogues varies between 4.3 ?M to 93 ?M. A mechanistic correlation of their anticancer activity has been described. The results of the cytotoxicity test of the compounds studies indicated that the ?,?-unsaturated ketonic moiety in parthenin plays an important role in the maintenance of the high level of cytotoxicity.Type: GrantFiled: March 5, 2009Date of Patent: December 17, 2013Assignee: Council of Scientific & Industrial ResearchInventors: Mahabalarao Sampath Kumar Halmuthur, Ajit Kumar Saxena, Subhash Chandra Taneja, Shashank Kumar Singh, Vijay Kumar Sethi, Naveed Ahmed Qazi, Sanghapal Damodhar Sawant, Mahendhar Reddy Doma, Abid Hussain Banday, Monika Verma, Ghularn Nabi Qazi
-
Patent number: 8609860Abstract: The present invention relates to a compound comprising an imine bond as an acid-labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceutical composition comprising said compound.Type: GrantFiled: June 21, 2010Date of Patent: December 17, 2013Assignee: KTB Tumorforschungsgesellschaft mbHInventors: André Warnecke, Ivonne Müller
-
Publication number: 20130331581Abstract: The present invention relates to 1,2,3-triazole containing artemisinin compounds and process for preparation thereof. Described herein is the synthesis, bioassay results and usefulness of the artemisinin derived compounds resulting from 1,3-di-polar cycloaddition reaction of artemisinin derived azide or alkyne with aliphatic or aromatic diazides. These 1,2,3-triazole containing artemisinin derived compounds embodied in this document are found to be active against various cancer cell-lines.Type: ApplicationFiled: February 14, 2012Publication date: December 12, 2013Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Bishwajit Saikia, Nabin Chandra Barua, Partha Pratim Saikia, Abhishek Goswami, Paruchuri Gangadhar Rao, Ajit Kumar Saxena, Nitasha Suri
-
Publication number: 20130330365Abstract: In one aspect, the invention relates to compounds having the formula X: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Adam D. Hughes, Melissa Fleury
-
Publication number: 20130330366Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Adam D. Hughes, Melissa Fleury
-
Patent number: 8597903Abstract: The present technology discloses biotinidase assay, biotinidase substrates (I) and a kit wherein the biotinidase substrate includes a label molecule separated from the biotin carbamoyl group by a linker X longer than about 4 ? but shorter than about 27 ?.Type: GrantFiled: March 10, 2010Date of Patent: December 3, 2013Assignee: Wallac OyInventors: Jarkko Karvinen, Pertti Hurskainen, Pekka Mattsson, Outi Mulari, Jari Peuralahti, Lassi Jaakkola
-
Publication number: 20130315841Abstract: Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted.Type: ApplicationFiled: March 15, 2013Publication date: November 28, 2013Inventor: Kay M. Brummond
-
Publication number: 20130310569Abstract: A method of synthesizing an ionic liquid, includes reacting a 1,2,3-triazole including at least one of a 4-substituent or a 5-substituent with a hydroxide compound having the formula R+OH? in a dehydration reaction, wherein R+ is an ionic liquid cation. R+ is a five-membered heterocyclic cation, an aromatic cation, a sulfonium cation, an ammonium cation, or a phosphonium cation. In a number of embodiments, R+ is a pyridinium cation, a bipyridinium cation, an amino pyridinium cation, a pyridazinium cation, an ozaxolium cation, a pyrazolium cation, an imidazolium cation, a pyramidinium cation, a triazolium cation, a thiazolium cation, an acridinium cation, a quinolinium cation, an isoquinolinium cation, an orange-acridinium cation, a benzotriazolium cation, a methimzolium cation, a sulfonium cation, an ammonium cation, or a phosphonium cation.Type: ApplicationFiled: May 21, 2013Publication date: November 21, 2013Inventors: Hunaid Nulwala, Robert Thompson, David Luebke, Erik Albenze
-
Patent number: 8586607Abstract: There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type II diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.Type: GrantFiled: July 23, 2009Date of Patent: November 19, 2013Assignee: Syddansk UniversitetInventors: Trond Ulven, Elisabeth Christiansen
-
Patent number: 8585938Abstract: UV absorbing compounds that are effective in blocking UV and short-wavelength blue light are disclosed. The UV absorbing compounds are particularly suitable for use in intraocular lens materials.Type: GrantFiled: March 29, 2013Date of Patent: November 19, 2013Assignee: Novartis AGInventors: David L. Jinkerson, Walter R. Laredo
-
Patent number: 8586201Abstract: An iridium complex is disclosed, which has a structure represented by the following formula (I): wherein each of Z1 and Z3 represents an atomic group for forming a nitrogen-containing heteroaryl group or a nitrogen-containing heterocycloalkenyl group; Z2 represents an atomic group for forming an aryl group, a heteroaryl group, a cycloalkenyl group or a heterocycloalkenyl group; Y represents an atomic group for forming a 5-membered nitrogen-containing heterocycloalkenyl group; each of R1, R2, R3 and R4 represents a hydrogen atom or a substituent; m is 1 or 2; a, b and d is 0 or any positive integer; and c is an integer of from 0 to 2.Type: GrantFiled: February 12, 2010Date of Patent: November 19, 2013Assignees: Chimei Innolux Corporation, National Tsing Hua UniversityInventors: Chien-Hong Cheng, Tai-Yen Chen, Hung-Hsin Shih, Chien-Te Wu, Kuan-Che Wang, Ching-In Wu, Huai-Ting Shih
-
Patent number: 8580970Abstract: A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion for a time sufficient to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt or copper metal. The process is preferably carried out in a solvent, such as an aqueous alcohol. Optionally, the process can be performed in a solvent that comprises a ligand for Cu(I) and an amine.Type: GrantFiled: March 5, 2012Date of Patent: November 12, 2013Assignee: The Scripps Research InstituteInventors: K. Barry Sharpless, Valery Fokin, Vsevold V. Rostovtsev, Luke Green, Fahmi Himo
-
Publication number: 20130295019Abstract: Disclosed are tris(triazolylmethyl)amine ligands, and kits and methods for labeling and/or imaging a biomolecule of interest in a subject or living system.Type: ApplicationFiled: August 5, 2011Publication date: November 7, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniInventors: Peng Wu, David Soriano del Amo, Wei Wang, Florence L. Marlow
-
Publication number: 20130289085Abstract: Compounds of Formula (I), and methods of making and using thereof, are described herein; wherein AR is an aryl group, ZBG is a Zinc Binding Group, and other substituents are as defined herein. The compounds can be administered as a pharmaceutically acceptable salt, prodrug, or solvate. The compounds may be useful to treat and/or prevent hyperproliferative disorders which may include hormone sensitive and hormone refractory prostate cancers. The compounds can be formulated with a pharmaceutically acceptable carrier and, optionally one or more pharmaceutically acceptable excipients, for enteral or parenteral administration.Type: ApplicationFiled: September 28, 2011Publication date: October 31, 2013Inventors: Adegboyega Oyelere, Berkley Gryder
-
Publication number: 20130289003Abstract: A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.Type: ApplicationFiled: October 25, 2011Publication date: October 31, 2013Inventors: Amjad Ali, Michael Man-Chu Lo, Robert K. Baker, Zhiqiang Guo, Brent Whitehead, Timothy J. Henderson, Edward Metzger, Lin Yan, Shrenik K. Shah, James Dellureficio, Jun Wang
-
Patent number: 8569350Abstract: Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.Type: GrantFiled: February 23, 2012Date of Patent: October 29, 2013Assignee: Rutgers, The State University of New JerseyInventors: William J. Welsh, Youyi Peng, Xin Wang, Susan M. Keenan, Qiang Zhang, Sonia Arora
-
Publication number: 20130281465Abstract: A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for the treatment or prevention of diseases such sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, pain, gastrointestinal diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, and hypertension, and of which the action relies on an orexin (OX) receptor antagonistic activity.Type: ApplicationFiled: December 16, 2011Publication date: October 24, 2013Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Dai Nozawa, Ryo Suzuki, Aya Futamura, Rie Shimono, Masahito Abe, Hiroshi Ohta, Yuko Araki
-
Publication number: 20130281503Abstract: The present disclosure provides methods and compositions useful for screening agents for activity in modulating response regulator signaling activity, which is, in turn, useful for determining whether these agents modulate biofilm formation or lowers the minimum inhibitory concentration (MIC) of an antibiotic, useful in determining or selecting optimum agents and/or agent dosages in modulating a biofilm of interest or lowering the minimum inhibitory concentration (MIC) of an antibiotic, and useful as a research tool for studying response regulators.Type: ApplicationFiled: April 26, 2013Publication date: October 24, 2013Applicant: North Carolina State UniversityInventor: North Carolina State University
-
Patent number: 8563585Abstract: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.Type: GrantFiled: March 3, 2009Date of Patent: October 22, 2013Assignee: Luna Innovations, IncorporatedInventors: Christopher L. Kepley, Robert P. Lenk, Stephen R. Wilson, Zhiguo Zhou, Darren K. MacFarland
-
Patent number: 8563526Abstract: The present invention relates to novel compounds of formula (A): in the form of a free base or of an addition salt with an acid. The invention also relates to process of preparation of compounds of formula (A), to composition comprising them and to their application in therapeutics and in particular in cancers.Type: GrantFiled: April 29, 2009Date of Patent: October 22, 2013Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Ling Peng, Palma Rocchi, Juan Iovanna, Yi Xia, Fanqi Qu, Jinqiao Wan, Yang Liu, Menghua Wang
-
Publication number: 20130274241Abstract: Compounds of Formula (I) are used for the treatment of inflammation and autoimmune disorders.Type: ApplicationFiled: December 16, 2011Publication date: October 17, 2013Applicant: MERCK SERONO S.A. - INTELLECTUAL PROPERTYInventors: Catherine Jorand-Lebrun, Stefano Crosignani, Jerome Dorbais, Tania Grippi-Vallotton, Adeline Pretre
-
Publication number: 20130272960Abstract: The present invention provides novel radioiodinated fatty acids. Also provided are methods of preparation of said radioiodinated fatty acids from non-radioactive precursors, as well as radiopharmaceutical compositions comprising such radioiodinated fatty acids. The invention also provides in vivo imaging methods using the radioiodinated fatty acids.Type: ApplicationFiled: December 15, 2011Publication date: October 17, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Michelle E. Avory, Harry John Wadsworth, Robert James Domett Nairne
-
Publication number: 20130272961Abstract: The present invention provides novel radioiodinated guanidines. Also provided are methods of preparation of said radioiodinated guanidines from non-radioactive precursors, as well as radiopharmaceutical compositions comprising such radioiodinated guanidines. The invention also provides in vivo imaging methods using the radioiodinated guanidines.Type: ApplicationFiled: December 20, 2011Publication date: October 17, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Michelle E. Avory, Robert James Domett Nairne, Harry Jon Wadsworth
-
Publication number: 20130267568Abstract: The invention relates to a compound of the formula wherein the substituents are as defined herein, and pharmaceutically acceptable salts of the compound of formula (1). The compounds of formula (1), and their salts, possess inflammation inhibiting properties and are therefore useful in the treatment and prevention of conditions related to inflammations, such as inflammatory joint diseases, or other diseases caused by chronic inflammation. This application relates to compounds of formula (1), methods for their preparation, pharmaceutical compositions comprising these compounds and their use for the preparation of medicaments for the treatment of humans and animals.Type: ApplicationFiled: April 5, 2012Publication date: October 10, 2013Inventors: Hubert Maehr, Donchu Wei
-
Publication number: 20130261130Abstract: The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is —CON—R3R4, —NR5COR6, —NHR7, —OR8, —SR9, —CH2NR10R11, —(CH2)2-R12, —CH?CH—R12, —C?C—R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.Type: ApplicationFiled: October 31, 2011Publication date: October 3, 2013Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Hans Allgeier
-
Publication number: 20130253203Abstract: Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.Type: ApplicationFiled: May 15, 2013Publication date: September 26, 2013Applicant: Nektar TherapeuticsInventors: Antoni Kozlowski, Jon McKannan, Samuel P. McManus
-
Publication number: 20130253004Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.Type: ApplicationFiled: December 6, 2011Publication date: September 26, 2013Applicant: Amira Pharmaceuticals, Inc.Inventors: Thomas Jon Seiders, Bowei Wang, John Howard Hutchinson, Nicholas Simon Stock, Deborah Volkots
-
Publication number: 20130253011Abstract: The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein A1, A2, A3, A4, R1, G1, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof.Type: ApplicationFiled: December 15, 2011Publication date: September 26, 2013Applicant: SYNGENTA PARTICIPATIONS AGInventors: Pierre Joseph Marcel Jung, Ottmar Franz Hueter, Peter Renold, Thomas Pitterna